/
Immunology
Autoimmune
7
Pipeline Programs↗
14
Active Trials↗
12
Companies Involved↗
Autoimmune is an early-stage landscape with 7 programs across 12 companies. The most active players are Sanofi. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 14
Phase 2
No programs
Approved
No programs
Analysis
Modality Breakdown
6programs
Small molecule350%
Cell therapy350%
Modality classified for 86% of 7 pipeline programs.
Analysis
Trial Status
15
clinical trials
Recruiting8 · 53%
Not yet recruiting5 · 33%
Completed1 · 7%
Active, not recruiting1 · 7%
Clinical Trials
Trial Activity
15 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)